Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
A legfontosabb adatok
- Ki végzi
- Neurocrine Biosciences
- Hol
- Ann Arbor, Atlanta, Aurora, Bethesda, Boston, Dallas, Great Neck, Indianapolis, Los Angeles, Minneapolis, New York, Philadelphia, Pittsburgh, Rochester, San Diego, San Francisco, Seattle, St Louis, Tulsa és Winston-Salem (Egyesült Államok)Mind a 20 helyszín megnézéseMég 17 másik országban, 42 helyszínen
- Állapot
- Fut, nem toboroz
- Fázis
- 3. fázis
- Résztvevők
- 182 fő vett részt
- Kezdés
- 2020. dec. 16.
- Várható befejezés
- 2027. aug.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Crinecerfont
- Placebo
- A regiszteradat frissítve
- 2026. május 11.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Be willing and able to adhere to the study procedures, including all requirements at the study center and return for the follow-up visit
- Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency
- Be on a stable steroid regimen
- Participants of childbearing potential must agree to use an acceptable method of contraception during the study
Ki nem vehet részt
- Have received any other investigational drug within 30 days before initial screening or plan to use an investigational drug (other than the study drug) during the study
- Have current substance dependence, or current substance (drug) or alcohol abuse
- Have had a blood loss ≥550 mL or donated blood or blood products within 8 weeks prior to the study
- Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy
- Have a clinically significant unstable medical condition or chronic disease other than CAH
- Have a history of cancer unless considered cured
- Have a known history of clinically significant arrhythmia or abnormalities on ECG
- Have a known hypersensitivity to any corticotropin releasing hormone receptor antagonists
- Have a diagnosis of any of the other known forms of classic CAH
- Are pregnant
Helyszínek itt: Egyesült Államok
Még 17 másik országban, 42 helyszínen
- Ann Arbor, MichiganHospital not named in the registry
- Atlanta, GeorgiaHospital not named in the registry
- Aurora, ColoradoHospital not named in the registry
- Bethesda, MarylandHospital not named in the registry
- Boston, MassachusettsHospital not named in the registry
- Dallas, TexasHospital not named in the registry
- Great Neck, New YorkHospital not named in the registry
- Indianapolis, IndianaHospital not named in the registry
- Los Angeles, CaliforniaHospital not named in the registry
- Minneapolis, MinnesotaHospital not named in the registry
- New YorkHospital not named in the registry
- Philadelphia, PennsylvaniaHospital not named in the registry
- Pittsburgh, PennsylvaniaHospital not named in the registry
- Rochester, New YorkHospital not named in the registry
- San Diego, CaliforniaHospital not named in the registry
- San Francisco, CaliforniaHospital not named in the registry
- Seattle, WashingtonHospital not named in the registry
- St Louis, MissouriHospital not named in the registry
- Tulsa, OklahomaHospital not named in the registry
- Winston-Salem, North CarolinaHospital not named in the registry
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency. The study consists of a 24-week randomized, double-blind, placebo-controlled period, followed by 1 year of active treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 20 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).
A vizsgálat 2 csoportja
- PlaceboPlacebo, összehasonlításként
Placebo capsule, administered orally, twice daily for 24 weeks, followed by active treatment with crinecerfont for at least 1 year.
Kezelés: Crinecerfont és Placebo
- CrinecerfontA vizsgált kezelés
Crinecerfont capsule, administered orally, twice daily for 24 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 1 year.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
- Publikációk
- Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.The New England journal of medicine, 2024
- A regiszteradat frissítve
- 2026. május 11.